Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab

J Clin Exp Hematop. 2023 Sep 28;63(3):201-204. doi: 10.3960/jslrt.23017. Epub 2023 Jul 28.

Authors

Masuho Saburi¹, Masanori Sakata¹, Yousuke Kodama¹, Keiichi Uraisami¹, Hiroyuki Takata¹, Yasuhiko Miyazaki¹, Junpei Wada², Shogo Urabe², Eiichi Ohtsuka¹

Affiliations

¹ Department of Hematology, Oita Prefectural Hospital, Oita, Japan.
² Department of Pathology, Oita Prefectural Hospital, Oita, Japan.

No abstract available

Keywords: MYC translocation; bendamustine; diffuse large B-cell lymphoma; polatuzumab vedotin.

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Bendamustine Hydrochloride
Humans
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Lymphoma, Large B-Cell, Diffuse* / genetics
Lymphoma, Large B-Cell, Diffuse* / pathology
Lymphoma, Non-Hodgkin* / drug therapy
Rituximab / therapeutic use

Substances

polatuzumab vedotin
Rituximab
Bendamustine Hydrochloride
Antibodies, Monoclonal